119 related articles for article (PubMed ID: 34740030)
1. Low LXA4, RvD1 and RvE1 levels may be an indicator of the development of hypertension.
Yücel H; Özdemir AT
Prostaglandins Leukot Essent Fatty Acids; 2021 Nov; 174():102365. PubMed ID: 34740030
[TBL] [Abstract][Full Text] [Related]
2. Low levels of pro-resolving lipid mediators lipoxin-A4, resolvin-D1 and resolvin-E1 in patients with rheumatoid arthritis.
Özgül Özdemir RB; Soysal Gündüz Ö; Özdemir AT; Akgül Ö
Immunol Lett; 2020 Nov; 227():34-40. PubMed ID: 32818598
[TBL] [Abstract][Full Text] [Related]
3. Plasma lipoxin A
Fedirko V; McKeown-Eyssen G; Serhan CN; Barry EL; Sandler RS; Figueiredo JC; Ahnen DJ; Bresalier RS; Robertson DJ; Anderson CW; Baron JA
Mol Carcinog; 2017 Aug; 56(8):1977-1983. PubMed ID: 28218420
[TBL] [Abstract][Full Text] [Related]
4. Effect of diclofenac on the levels of lipoxin A4 and Resolvin D1 and E1 in the post-ERCP pancreatitis.
Zhao XW; Bao JJ; Hu C; Ding H; Liu XC; Mei Q; Xu JM
Dig Dis Sci; 2014 Dec; 59(12):2992-6. PubMed ID: 25030943
[TBL] [Abstract][Full Text] [Related]
5. Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer's disease.
Kantarci A; Aytan N; Palaska I; Stephens D; Crabtree L; Benincasa C; Jenkins BG; Carreras I; Dedeoglu A
Exp Neurol; 2018 Feb; 300():111-120. PubMed ID: 29126887
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal assessment of leukotriene B4, lipoxin A4, and resolvin D1 plasma levels in pregnant women with risk factors for preeclampsia.
Perucci LO; de Castro Pinto KM; da Silva SPG; Lage EM; Teixeira PG; Barbosa AS; Alpoim PN; de Sousa LP; Talvani A; Dusse LMS
Clin Biochem; 2021 Dec; 98():24-28. PubMed ID: 34492288
[TBL] [Abstract][Full Text] [Related]
7. Effect of specialized pro-resolving lipid mediators in the regulation of vascular tone and inflammation in human saphenous vein.
Celik Z; Ozen G; Sunar S; Turkyilmaz S; Turkyilmaz G; Kavala AA; Teskin O; Dogan BSU; Topal G
Prostaglandins Other Lipid Mediat; 2023 Dec; 169():106786. PubMed ID: 37806440
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.
Jin Y; Arita M; Zhang Q; Saban DR; Chauhan SK; Chiang N; Serhan CN; Dana R
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4743-52. PubMed ID: 19407006
[TBL] [Abstract][Full Text] [Related]
9. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation.
Weiss GA; Troxler H; Klinke G; Rogler D; Braegger C; Hersberger M
Lipids Health Dis; 2013 Jun; 12():89. PubMed ID: 23767972
[TBL] [Abstract][Full Text] [Related]
10. Combination of resolvin E1 and lipoxin A4 promotes the resolution of pulpitis by inhibiting NF-κB activation through upregulating sirtuin 7 in dental pulp fibroblasts.
Liu X; Wang C; Pang L; Pan L; Zhang Q
Cell Prolif; 2022 May; 55(5):e13227. PubMed ID: 35411569
[TBL] [Abstract][Full Text] [Related]
11. 15-epi-Lipoxin A
Sham HP; Walker KH; Abdulnour RE; Krishnamoorthy N; Douda DN; Norris PC; Barkas I; Benito-Figueroa S; Colby JK; Serhan CN; Levy BD
J Immunol; 2018 Apr; 200(8):2757-2766. PubMed ID: 29523657
[TBL] [Abstract][Full Text] [Related]
12. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actions.
Tian H; Lu Y; Sherwood AM; Hongqian D; Hong S
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3613-20. PubMed ID: 19443724
[TBL] [Abstract][Full Text] [Related]
13. Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation.
Norris PC; Skulas-Ray AC; Riley I; Richter CK; Kris-Etherton PM; Jensen GL; Serhan CN; Maddipati KR
Sci Rep; 2018 Dec; 8(1):18050. PubMed ID: 30575798
[TBL] [Abstract][Full Text] [Related]
14. Resolvin D1 and E1 promote resolution of inflammation in rat cardiac fibroblast in vitro.
Salas-Hernández A; Espinoza-Pérez C; Vivar R; Espitia-Corredor J; Lillo J; Parra-Flores P; Sánchez-Ferrer CF; Peiró C; Díaz-Araya G
Mol Biol Rep; 2021 Jan; 48(1):57-66. PubMed ID: 33459958
[TBL] [Abstract][Full Text] [Related]
15. Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein.
Lehmann C; Homann J; Ball AK; Blöcher R; Kleinschmidt TK; Basavarajappa D; Angioni C; Ferreirós N; Häfner AK; Rådmark O; Proschak E; Haeggström JZ; Geisslinger G; Parnham MJ; Steinhilber D; Kahnt AS
FASEB J; 2015 Dec; 29(12):5029-43. PubMed ID: 26289316
[TBL] [Abstract][Full Text] [Related]
16. Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse.
Harrison JL; Rowe RK; Ellis TW; Yee NS; O'Hara BF; Adelson PD; Lifshitz J
Brain Behav Immun; 2015 Jul; 47():131-40. PubMed ID: 25585137
[TBL] [Abstract][Full Text] [Related]
17. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling.
Elajami TK; Colas RA; Dalli J; Chiang N; Serhan CN; Welty FK
FASEB J; 2016 Aug; 30(8):2792-801. PubMed ID: 27121596
[TBL] [Abstract][Full Text] [Related]
18. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution.
Fredman G; Serhan CN
Biochem J; 2011 Jul; 437(2):185-97. PubMed ID: 21711247
[TBL] [Abstract][Full Text] [Related]
19. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin.
Salic K; Morrison MC; Verschuren L; Wielinga PY; Wu L; Kleemann R; Gjorstrup P; Kooistra T
Atherosclerosis; 2016 Jul; 250():158-65. PubMed ID: 27236706
[TBL] [Abstract][Full Text] [Related]
20. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer.
Janakiram NB; Rao CV
Curr Mol Med; 2009 Jun; 9(5):565-79. PubMed ID: 19601807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
